Yingyu Ma
Assistant Professor
Department of Pharmacology & Therapeutics
Roswell Park Cancer Institute
United States of America
Biography
Dr. Yingyu Ma works as Assistant Professor of Oncology in the Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. She also works as associate member for Molecular Pharmacology and Cancer Therapeutics Graduate Program and Experimental Therapeutics CCSG (Comprehensive Cancer Support Grant) Program. The main focus of our research is: 1,25D3 regulation of apoptosis, migration and invasion in cancer. Her current research focuses on the regulation of miRNAs and their target genes involved in bladder cancer cell migration and invasion by 1,25D3, and the potential underlying mechanisms. She is also interested in applying 1,25D3 in the combinational treatment with chemotherapeutic agents to potentiate their anti-tumor effects.
Research Interest
regulation of miRNAs and their target genes involved in bladder cancer cell migration and invasion by 1,25D3, and the potential underlying mechanisms. She is also interested in applying 1,25D3 in the combinational treatment with chemotherapeutic agents to potentiate their anti-tumor effects.
Publications
-
Ma Y, Yu WD, Trump DL, Johnson CS, (2010) 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 116: 3294
-
Ma Y, Yu WD, Su B, Seshadri M, Luo W, et al. (2013) Regulation of Motility, Invasion and Metastatic Potential of Squamous Cell Carcinoma by 1,25D3. Cancer 119: 563
-
Ma Y, Hu Q, Luo W, Pratt RN, Glenn ST, et al. (2015) 1α,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 148: 166-71
